Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Haley Hendrick
Observed name:
H. Hendrick
Institutions:
University of Maryland, Baltimore,
National Cancer Institute,
University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
Observed institutions:
University of Maryland, Baltimore,
National Cancer Institute,
University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
ORCID:
0009-0005-7534-5454
Observed ORCID:
0009-0005-7534-5454
OpenAlex ID:
A5103309140
Hypoxic Memory Mediates Prolonged Tumor-Intrinsic Type I Interferon Suppression to Promote Breast Cancer Progression
2024
·
Oihana Iriondo
, Desirea Mecenas
, et al.
·
Cancer Research
·
21
PDF
Supplemental Figure 3 from Identification and Validation of the ESR1 Y537S Mutant–Enriched Enhancer and Its Downstream Target IGFBP3
2026
·
Yonatan Amzaleg
, Desirea Mecenas
, et al.
Supplemental Figure 2 from Identification and Validation of the ESR1 Y537S Mutant–Enriched Enhancer and Its Downstream Target IGFBP3
2026
·
Yonatan Amzaleg
, Desirea Mecenas
, et al.
Supplemental Table 1 from Identification and Validation of the ESR1 Y537S Mutant–Enriched Enhancer and Its Downstream Target IGFBP3
2026
·
Yonatan Amzaleg
, Desirea Mecenas
, et al.
Figure 3 from Identification and Validation of the ESR1 Y537S Mutant–Enriched Enhancer and Its Downstream Target IGFBP3
2026
·
Yonatan Amzaleg
, Desirea Mecenas
, et al.
Figure 1 from Identification and Validation of the ESR1 Y537S Mutant–Enriched Enhancer and Its Downstream Target IGFBP3
2026
·
Yonatan Amzaleg
, Desirea Mecenas
, et al.
Table 1 from Identification and Validation of the ESR1 Y537S Mutant–Enriched Enhancer and Its Downstream Target IGFBP3
2026
·
Yonatan Amzaleg
, Desirea Mecenas
, et al.
Figure 5 from Identification and Validation of the ESR1 Y537S Mutant–Enriched Enhancer and Its Downstream Target IGFBP3
2026
·
Yonatan Amzaleg
, Desirea Mecenas
, et al.
Supplemental Figure 1 from Identification and Validation of the ESR1 Y537S Mutant–Enriched Enhancer and Its Downstream Target IGFBP3
2026
·
Yonatan Amzaleg
, Desirea Mecenas
, et al.
Figure 4 from Identification and Validation of the ESR1 Y537S Mutant–Enriched Enhancer and Its Downstream Target IGFBP3
2026
·
Yonatan Amzaleg
, Desirea Mecenas
, et al.
Data from Identification and Validation of the ESR1 Y537S Mutant–Enriched Enhancer and Its Downstream Target IGFBP3
2026
·
Yonatan Amzaleg
, Desirea Mecenas
, et al.
Figure 2 from Identification and Validation of the ESR1 Y537S Mutant–Enriched Enhancer and Its Downstream Target IGFBP3
2026
·
Yonatan Amzaleg
, Desirea Mecenas
, et al.
Supplemental Figure 4 from Identification and Validation of the ESR1 Y537S Mutant–Enriched Enhancer and Its Downstream Target IGFBP3
2026
·
Yonatan Amzaleg
, Desirea Mecenas
, et al.
Supplemental Table 2 from Identification and Validation of the ESR1 Y537S Mutant–Enriched Enhancer and Its Downstream Target IGFBP3
2026
·
Yonatan Amzaleg
, Desirea Mecenas
, et al.
Supplemental Table 3 from Identification and Validation of the ESR1 Y537S Mutant–Enriched Enhancer and Its Downstream Target IGFBP3
2026
·
Yonatan Amzaleg
, Desirea Mecenas
, et al.
Identification and Validation of the ESR1 Y537S Mutant–Enriched Enhancer and Its Downstream Target IGFBP3
2026
·
Yonatan Amzaleg
, Desirea Mecenas
, et al.
·
Cancer Research Communications
PDF
Single-Cell Profiling of Apoptotic Resistance in Patient-Derived Xenografts and Primary Circulating Tumor Cells Using TetherChip
2026
·
Darin E. Gilchrist
, Keyata N. Thompson
, et al.
·
ACS Applied Materials & Interfaces
Table S4 from Hypoxic Memory Mediates Prolonged Tumor-Intrinsic Type I Interferon Suppression to Promote Breast Cancer Progression
2026
·
Oihana Iriondo
, Desirea Mecenas
, et al.
Figure S7 from Hypoxic Memory Mediates Prolonged Tumor-Intrinsic Type I Interferon Suppression to Promote Breast Cancer Progression
2026
·
Oihana Iriondo
, Desirea Mecenas
, et al.
Table S5 from Hypoxic Memory Mediates Prolonged Tumor-Intrinsic Type I Interferon Suppression to Promote Breast Cancer Progression
2026
·
Oihana Iriondo
, Desirea Mecenas
, et al.
Figure S6 from Hypoxic Memory Mediates Prolonged Tumor-Intrinsic Type I Interferon Suppression to Promote Breast Cancer Progression
2026
·
Oihana Iriondo
, Desirea Mecenas
, et al.
Table S6 from Hypoxic Memory Mediates Prolonged Tumor-Intrinsic Type I Interferon Suppression to Promote Breast Cancer Progression
2026
·
Oihana Iriondo
, Desirea Mecenas
, et al.
Table S3 from Hypoxic Memory Mediates Prolonged Tumor-Intrinsic Type I Interferon Suppression to Promote Breast Cancer Progression
2026
·
Oihana Iriondo
, Desirea Mecenas
, et al.
Figure S1 from Hypoxic Memory Mediates Prolonged Tumor-Intrinsic Type I Interferon Suppression to Promote Breast Cancer Progression
2026
·
Oihana Iriondo
, Desirea Mecenas
, et al.
Figure S4 from Hypoxic Memory Mediates Prolonged Tumor-Intrinsic Type I Interferon Suppression to Promote Breast Cancer Progression
2026
·
Oihana Iriondo
, Desirea Mecenas
, et al.
Show more works
View as search
Works count:
51
Citation count:
21
H-index:
1
I10-index:
1
Year
Topic
Type